Amansa Investments Invests Rs 250 Crore in Rubicon Research Ahead of IPO
Amansa Investments Ltd has invested Rs 250 crore in pharma formulation firm Rubicon Research Ltd through a pre-initial public offering (IPO) funding round.
Pre-IPO Funding Round Details
As part of the transaction, General Atlantic Singapore RR Pte Ltd, one of Rubicon Research’s promoters, transferred 51.60 lakh equity shares to Amansa Investments at Rs 484.47 per share, amounting to Rs 250 crore, the company said in a public announcement.
Rubicon Research’s Proposed IPO
Rubicon Research is expected to come out with its maiden public issue by the end of this year, people familiar with the matter said. The company’s proposed IPO consisted of a fresh issue of equity shares worth Rs 500 crore alongside an offer-for-sale of shares valued Rs 585 crore.
Utilization of Proceeds
The company plans to utilise proceeds from the fresh issue for payment of debt, supporting inorganic growth through unidentified acquisitions as well as other strategic initiatives and general corporate purposes.
Rubicon Research’s Business Overview
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States.
Recent Developments
In June, Rubicon Research completed the acquisition of Alkem Laboratories’ formulations manufacturing facility in Pithampur, Madhya Pradesh in an all-cash deal for Rs 149 crore.
USFDA Approvals and Product Portfolio
As on March 31, 2024, the company had a portfolio of 69 products approved by the USFDA, 19 new drugs awaiting USFDA’s nod and 46 products in various stages of development.
Rubicon Research has two US FDA-inspected research and development (R&D) facilities, one each in India and Canada, and two manufacturing facilities in India with multiple accreditations from multiple regulatory agencies such as USFDA, Food and Drugs Administration, Maharashtra (WHO-GMP accreditation) and Health Canada.
Investment Implications
The investment by Amansa Investments ahead of the IPO is a significant development for Rubicon Research, indicating confidence in the company’s growth potential. This investment is expected to provide a boost to the company’s plans for expansion and strategic initiatives.
Conclusion
In conclusion, the investment of Rs 250 crore by Amansa Investments in Rubicon Research is a positive development for the company and the pharma sector as a whole. With its strong product portfolio, research and development capabilities, and manufacturing facilities, Rubicon Research is well-positioned for growth in the regulated markets, particularly in the United States.
For investors, this development is a significant indicator of the company’s potential for future growth. As the company prepares for its maiden IPO, investors should keep a close watch on the developments and consider the investment opportunities in the pharma sector.